Gideon Capital Advisors’s AbbVie ABBV Stock Holding History

Gideon Capital Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-6,774	Closed	-$600K	–	2
2019 Q4	$600K	Buy	+6,774	New	+$562K	0.21%	157
2019 Q3	–	Sell	-14,753	Closed	-$1.07M	–	280
2019 Q2	$1.07M	Buy	14,753 +8,825	+149%	+$694K	0.37%	104
2019 Q1	$478K	Buy	+5,928	New	+$485K	0.17%	181
2018 Q4	–	Sell	-2,436	Closed	-$230K	–	359
2018 Q3	$230K	Buy	+2,436	New	+$231K	0.11%	295
2018 Q1	–	Sell	-6,048	Closed	-$585K	–	327
2017 Q4	$585K	Buy	6,048 +1,575	+35%	+$148K	0.52%	41
2017 Q3	$397K	Sell	4,473 -1,073	-19%	-$81.7K	0.39%	76
2017 Q2	$402K	Sell	5,546 -10,470	-65%	-$704K	0.44%	81
2017 Q1	$1.04M	Buy	16,016 +9,345	+140%	+$588K	0.62%	16
2016 Q4	$418K	Buy	+6,671	New	+$407K	0.27%	130
2015 Q3	–	Sell	-6,344	Closed	-$426K	–	205
2015 Q2	$426K	Buy	+6,344	New	+$414K	0.18%	150
2015 Q1	–	Sell	-6,497	Closed	-$425K	–	216
2014 Q4	$425K	Buy	6,497 +1,724	+36%	+$109K	0.2%	133
2014 Q3	$276K	Buy	+4,773	New	+$265K	0.11%	213

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Gideon Capital Advisors's ABBV Position: Q1 2020 in Review

Gideon Capital Advisors sold out of AbbVie (ABBV) in Q1 2020, closing a stake of 6,774 shares — an estimated $600K sold.

Gideon Capital Advisors first reported a position in ABBV in Q3 2014 and held it in 12 quarters. The position peaked at $1.07M in Q2 2019. 2,226 funds tracked by Wall St. Rank hold ABBV as of Q1 2020.

Gideon Capital Advisors reported no remaining AbbVie position as of Q1 2020 after selling out during the quarter.
Gideon Capital Advisors sold 6,774 AbbVie shares in Q1 2020, an estimated $600K.
Gideon Capital Advisors first reported a position in AbbVie in Q3 2014 and held it in 12 quarters.
Gideon Capital Advisors's AbbVie position peaked at $1.07M in Q2 2019.
2,226 funds tracked by Wall St. Rank held AbbVie as of Q1 2020.

Based on Gideon Capital Advisors's 13F filing for Q1 2020.